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Abstract
Introduction: The pathophysiology of sepsis-associated encephalopathy (SAE) is not entirely clear. One of the possible 
underlying mechanisms is the alteration of the cerebral microvascular function induced by the systemic inflammation. 
The aim of the present work was to test whether cerebral vasomotor-reactivity is impaired in patients with SAE.
Methods: Patients fulfilling the criteria of clinical sepsis and showing disturbance of consciousness of any severity were 
included (n = 14). Non-septic persons whithout previous diseases affecting cerebral vasoreactivity served as controls (n 
= 20). Transcranial Doppler blood flow velocities were measured at rest and at 5, 10, 15 and 20 minutes after 
intravenous administration of 15 mg/kgBW acetazolamide. The time course of the acetazolamide effect on cerebral 
blood flow velocity (cerebrovascular reactivity, CVR) and the maximal vasodilatory effect of acetazolemide 
(cerebrovascular reserve capacity, CRC) were compared among the groups.
Results: Absolute blood flow velocities after adminsitration of the vasodilator drug were higher among control 
subjects than in SAE. Assessment of the time-course of the vasomotor reaction showed that patients with SAE reacted 
slower to the vasodilatory stimulus than control persons. When assessing the maximal vasodilatory ability of the 
cerebral arterioles to acetazolamide during vasomotor testing, we found that patients with SAE reacted to a lesser 
extent to the drug than did control subjects (CRC controls:46.2 ± 15.9%, CRC SAE: 31,5 ± 15.8%, P < 0.01).
Conclusions: We conclude that cerebrovascular reactivity is impaired in patients with SAE. The clinical significance of 
this pathophysiological finding has to be assessed in further studies.
Introduction
Sepsis-associated encephalopathy is defined as a diffuse
cerebral dysfunction induced by the systemic response to
the infection without clinical or laboratory evidence of
direct infectious involvement of the central nervous sys-
tem [1]. Previous clinical observations have shown that
the brain is often the first organ to be affected by sepsis,
preceeding the clinical symptoms of other organ manifes-
tations. According to the studies of Wilson and col-
leagues and Young and colleagues, electroencephalogram
(EEG) may be abnormal in 87% of patients with bacteri-
emia. They diagnosed 70% with disturbance of con-
sciousness of differing severity ranging from somnolence
to coma [1-3]. Ebersoldt and colleagues, reviewing sepsis-
associated delirium, reported on a prevalence ranging
from 9 to 71% [4]. The exact pathomechanism involved is
not yet fully understood. It is believed that microcircula-
tory alterations, disturbance of cerebral autoregulation,
damage of the blood-brain barrier, branched chain/aro-
matic amino acid inbalance and the direct effect of the
inflammatory process (e.g. free radicals, oxydative stress,
cytokines, excitotoxicity apoptosis) on glial cells may play
a decisive role. Sepsis-related encephalopathy is most
likely to be a multifactorially determined syndrome [5].
When assessing cerebral microvascular contributing
factors, in previous human investigations Matta and Stow
[6] found cerebral autoregulation and carbon dioxide
reactivity to be normal in patients with sepsis, whereas
Terborg and colleagues reported on severely disturbed
vasomotor reactivity (VMR) [7]. In the past two decades,
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Page 2 of 7different stimuli have been used to test cerebral autoregu-
lation and metabolic regulation, such as altering arterial
partial pressure of carbon dioxide (pCO2) either by inha-
lation of carbon dioxide or by changing respiratory rate
(carbon dioxide reactivity), breath holding test (carbon
dioxide reactivity), decreasing systemic blood pressure
and therewith cerebral perfusion pressure (cerebral auto-
regulation) and intravenous injection of acetazolamide.
Acetazolamide, the reversible inhibitor of the enzyme
carbonic anhydrase, has been used to test cerebral VMR
in various diseases and conditions [8]. Disturbed cerebro-
vascular reactivity (CVR) as a sign of cerebral microvas-
cular alterations has been demonstrated in patients with
diabetes mellitus [9,10], arterial hypertension [11], sys-
temic lupus erythematosus [12], in subjects hemodynam-
ically significant stenoses and occlusions of the carotid
arteries [13]. With respect to the debated involvement of
the above cerebral microvascular alterations, in the pres-
ent study we intended to test whether acetazolamide-
induced cerebral VMR is altered in patients with sepsis-
associated encephalopathy. To the best of our knowledge
this is the first study that uses the transcranial Doppler-
acetazolamide test to assess cerebral VMR in sepsis-
related encephalopathy.
Materials and methods
The study was approved by the local Medical Ethics
Committee of the Debrecen University Health and Medi-
cal Science Centre. Patients fulfilling the criteria of clini-
cal sepsis according to the guidelines of the American
College of Chest Physicians/Society of Critical Care Med-
icine (ACCP/SCCM) Consensus Conference Committee
[14] were enrolled in the study. Those with hemodynamic
instability, in need of hemodynamic support or with signs
of hypoperfusion of the different organs were excluded.
Patients were not under mechanical ventilation prior to
or during the study. Patients were selected and screened
during daily rounds on the postoperative surgical wards
or from the multidisciplinary surgical ICU.
Sepsis-related encephalopathy was defined as a combi-
nation of the following: patients had to meet the criteria
of clinical sepsis and had to show disturbance of con-
sciousness or alertness of any severity. Any other meta-
bolic causes of conscious disturbance were excluded
(hypoxemia, hyper-or hypoglycemia, increased serum
urea, creatinine or ammonia levels). A certified neurolo-
gist (BF) performed a detailed neurological assessment of
all the patients in order to exclude direct infectious
involvement of the central nervous system (such as men-
ingitis or encephalitis). Sedative drugs were not adminis-
tered before the neurological assessment. Consciousness/
alertness disturbance was graded by two scales: the Rich-
mond Agitation-Sedation Scale (RASS) and the Ramsay
scores. The different categories of these scoring systems
are described elsewhere in detail [15]. As septic patients
suffered from altered consciousness, their nearest rela-
tives were asked to give informed consent. When sepsis
and encephalopathy were diagnosed, patients were trans-
ferred to the ICU and a continous monitoring of arterial
blood pressure, echocardiography, pulse oxymetry was
initiated. This made it possible to perform arterial blood
gas analysis every five minutes after acetazolamide
administration.
Transcranial Doppler measurements were performed
in the supine position using a Rimed Digilite Transcranial
Doppler sonograph (Rimed Ltd, Raanana, Israel). A 2
MHz probe was used for insonation, and sample volume,
gain and power were kept constant during the investiga-
tion. Temporal window was used for insonation, probes
were fixed by LMY-2 probe holder (Rimed Ltd, Raanana,
Israel). The device enabled the assessment of the best
available signal of the middle cerebral artery between the
depths of 45 to 55 mm. Systolic, diastolic and mean blood
flow velocities were registered, and pulsatility indices
were calculated by the device. After a blood flow velocity
measurement was performed at rest, 15 mg/kg acetazol-
amide (Diamox, Lederle Pharmaceuticals, Carolina,
Puerto Rico, USA) was injected intravenously. As pro-
posed in previous studies [8], blood flow velocities were
continously registered until 20 minutes after injection of
the vasodilatory stimulus. CVR was defined as the per-
centage increase of the middle cerebral artery mean
blood flow velocity after administration of acetazolamide.
CVR was calculated as follows:
where MCAVACZ is the middle cerebral artery mean
blood flow velocity measured at 5, 10, 15 and 20 minutes
after acetazolamide, and MCAVrest is the middle cerebral
artery mean blood flow velocity measured at rest. Cere-
brovascular reserve capacity (CRC; the maximal percent-
age increase of the blood flow velocity after
acetazolamide administration), was calculated as follows:
where MCAVACZmax is the highest mean blood flow
velocity in the middle cerebral artery within 20 minutes
after administration of acetazolamide.
Transcranial Doppler measurements were performed
in 20 age- and sex-matched persons, who were free of
sepsis, diabetes mellitus, hypertension, significant
stenoses of the cerebral arteries or any known diseases
which, according to our present knowledge, could have
CVR MCA MCAVACZ rest= ( )/−
CRC (MCAVACZm x= −
MCAVrest
MCAVrest)/MCAVresta
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trols for the study. In these subjects arterial sampling for
blood gas analysis was only performed at resting state,
because inserting a radial artery catheter or serial arterial
sampling during the whole study was considered unethi-
cal.
Statistical analysis
Means and standard deviations were reported for all val-
ues. Before performing statistical comparisons of the
parameters, a normality test was used. Parameters with
normal distribution were compared with the appropriate
unpaired t-tests. Repeated measure analysis of variance
was used to detect differences in MCAV and CVR values
after acetazolemide administration. When significant dif-
ferences were detected, pairwise comparisons were per-
formed between the groups using the Mann-Whitney U
test. Differences were accepted as statistically significant
if P value was less than 0.05.
Results
Fourteen patients with sepsis-associated encephalopathy
and 20 control persons were enrolled. Blood pressure val-
ues assessed by arterial blood pressure did not change
during the acetazolamide testing. During the study, slight
hyperventilation was observed, but any deterioration of
the patients' status did not occur during or after acetazol-
amide. The results of the most important clinical and lab-
oratory data of septic patients and controls are
summarized in Table 1. From these data it can be seen
that blood pressures and blood gas analysis parameters
were comparable in the two groups at rest. In septic
patients, pH slightly decreased, while pCO2 and partial
pressure of oxygen slightly increased during the acetazol-
amide test. The distribution of the Ramsay scales were in
the septic groups as follows: Ramsay 1 = 6 cases, Ramsay
3 = 4 cases, Ramsay 4 = 4 cases. There were five cases
with RASS +1 and a further eight cases with RASS -1.
Thus, in all cases either a sepsis-related delirious state or
somnolence was present.
The results of the transcranial Doppler measurements
are summarized in Table 2. Resting systolic blood flow
velocities did not differ, but the mean and the diastolic
blood flow velocities were lower in the group with sepsis-
associated encephalopathy. It has to be noted that pulsa-
tility indices were higher at the resting state in patients
with sepsis-related encephalopathy and this difference
remained unchanged after administration of acetazol-
amide. Absolute blood flow velocities after the vasodila-
tor drug were higher among control subjects than in
septic patients. In a further analysis we checked the time-
course of the vasomotor reaction to acetazolamide. As
shown in Figure 1, patients with sepsis-associated
encephalopathy reacted slower to the vasodilatory stimu-
lus than control persons. When assessing the maximal
vasodilatory ability of the cerebral arterioles to acetazol-
amide during 20 minutes of vasomotor testing, we found
that patients with sepsis-associated encephalopathy
reacted to the drug to a lesser extent than control sub-
jects. The results are depicted in Figure 2.
Discussion
In the present study we found that cerebral VMR is
impaired in patients with sepsis-associated encephalopa-
thy. It is also clear from our results that not only maximal
vasodilative capacity (CRC) but also the time-course of
the vasodilative effect (CVR) is affected after administra-
tion of acetazolamide in septic patients. Thus, the reac-
tion of the cerebral arterioles to the vasodilatory stimulus
is not only lower in magnitude, but also occurs slower in
patients with sepsis-associated encephalopathy.
When analyzing absolute blood flow velocities in the
middle cerebral artery, it is clear that they are lower in
patients with sepsis-associated encephalopathy com-
pared with non-septic control persons after aceta-
zolemide stimulation. A decrease in the blood flow
velocity measured within the middle cerebral artery may
theoretically be explained in two ways: either the large
and medium-size vessel (the middle cerebral artery) is
dilated or there is a vasoconstriction at the level of resis-
tance arterioles of its corresponding territory. Although
this question cannot be answered based only on the abso-
lute blood flow velocity values, taking the pulsatility indi-
ces into account, the higher pulsatility index among
patients with sepsis-associated encephalopathy is more
likely to indicate vasoconstriction of the cerebral arteri-
oles. It has been shown previously that an increase in
resistance distal to the site of insonation results in an
increased blood flow pulsatility [16]. Thus, based on our
results, decreased cerebral blood flow velocities along
with higher pulsatility indices in patients with sepsis-
associated encephalopathy can be ascribed to the vaso-
constriction of the resistance arterioles. These results are
in accordance with previous studies stating that cerebral
blood flow is reduced and cerebrovascular resistance is
increased in sepsis-associated encephalopathy [1,17]. It
seems that general vasodilation does not affect the brain
circulation in sepsis; instead a vasoconstriction of the
resistance arterioles occurs. This is the explanation for
the findings of Matta and Stow, who found that sepsis-
induced vasoparalysis does not involve the cerebral vas-
culature [6].
There are numerous factors in sepsis that may contrib-
ute to the vasoconstriction of the brain resistance arteri-
oles. First, in animal experiments it has been
demonstrated that the blood-brain barrier, which nor-
mally maintains a homeostatic environment for brain
cells, becomes leaky within the first hours of endotox-
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levels of endogenous catecholamines to directly influence
cerebrovascular resistance [18]. Second, it is believed that
cytokines and ILs produced during the course of the sep-
sis cascade may alter the activity of the endothelial nitric
oxide synthase. The inhibition of endothelial nitric oxide
synthase leads to the impairment of the microcirculation
of the brain by causing vasoconstriction [1]. Finally, alter-
ations of the coagulation system resulting in microthrom-
boses and microinfarctions as seen in sepsis may also
contribute to the microvascular dysfunction [19].
The goal of cerebral autoregulation and metabolic vaso-
reactivity testing is to see whether the brain circulation is
able to adopt to sudden and critical changes of blood
pressure (autoregulation) or metabolic demands (meta-
bolic regulation). From the previous clinical investiga-
tions and animal experiments it is clear that cerebral
arterioles of 40 to 200 μm in diameter are common actors
of both autoregulatory and metabolic response of the
brain circulation. Different stimuli have been used to test
cerebral autoregulation and metabolic regulation, such as
altering pCO2 (carbon dioxide reactivity), breath holding
test (carbon dioxide reactivity), decreasing systemic
blood pressure and therewith cerebral perfusion pressure
(cerebral autoregulation) and intravenous injection of
acetazolamide. Basically, there are two main factors to
take into account during VMR tests: the maximal vasodi-
lative capacity (CRC) and the time-course of the reaction
(CVR) [8]. In the present study we used intravenous
acetazolamide to assess the cerebral vasomotor response.
For the sake of clarity we intend to explain the concept
of transcranial Doppler acetazolamide tests. Acetazol-
amide is a reversible inhibitor of the carbonic anhydrase,
which is located at the surface of the erythrocytes. The
enzyme catalyses the following reaction: CO2 + H2O T
H2CO3 T H+ + HCO3). It also induces a slight temporary
Table 1: Results of the most important clinical or laboratory parameters before in septic and in control patients
Sepsis Control P value
Systolic BP (mmHg) 117.9 ± 10.3 113.5 ± 8.7 0.20
Diastolic BP (mmHg) 69.7 ± 5.9 75.0 ± 5.4 0.01
Mean BP (mmHg) 84.7 ± 7.6 87.8 ± 5.3 0.21
Arterial pH
0 minutes 7.39 ± 0.04 7.40 ± 0.03 0.48
5 minutes 7.38 ± 0.04 NA -
10 minutes 7.37 ± 0.03 NA -
15 minutes 7.37 ± 0.04 NA -
20 minutes 7.37 ± 0.04 NA -
Arterial pCO2 (mmHg)
0 minutes 36.8 ± 3.4 38.9 ± 1.96 0.11
5 minutes 38.2 ± 3.5 NA -
10 minutes 41.0 ± 4.4 NA -
15 minutes 40.8 ± 3.9 NA -
20 minutes 41.3 ± 4.9 NA -
Arterial pO2 (mmHg)
0 minutes 87.0 ± 9.7 83.7 ± 3.46 0.07
5 minutes 91.5 ± 11.2 NA -
10 minutes 91.5 ± 9.3 NA -
15 minutes 91.2 ± 8.9 NA -
20 minutes 90.0 ± 9.0 NA -
WBC count (G/l) 15.1 ± 6.4 5.93 ± 1.84 < 0.001
PCT 8.89 ± 8.7 NA -
Means and standard deviations are shown.
BP: blood pressure; NA: not available; PCO2: partial pressure of carbon dioxide; PCT: procalcitonin; PO2: partial pressure of oxygen; WBC: white 
blood cell count.
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results in vasodilation of the cerebral arterioles, most
probably through inducing nitric oxide synthesis [8]. As
described above, cerebral arterioles are key actors in cere-
bral autoregulation and metabolic regulation. Dilation of
these vessels results in a decrease of cerebrovascular
resistance. As shown in Figure 3, transcranial Doppler
measurements can be performed at the level of the mid-
dle cerebral artery and cerebral arterioles cannot be
directly assessed. When an arteriolar vasodilation occurs,
the cerebrovascular resistance of the corresponding arte-
rial territory decreases, resulting in an increase of the
cerebral blood flow velocity measured in the middle cere-
bral artery. Thus, cerebral arteriolar function cannot be
directly measured. Only changes of the cerebrovascular
resistance induced by acetazolamide can be indirectly
assessed by measuring cerebral blood flow velocities in
the middle-sized arteries of the corresponding territory.
It has to be noted that there are some limitations of our
study. Transcranial Doppler does not measure cerebral
blood flow. It measures cerebral blood flow velocity, the
changes of which are not equal, but only proportional to
changes of cerebral blood flow. A further limitation is the
lack of arterial pCO2 monitoring in the control group.
In our study, a less intensive CVR was detected in
patients with sepsis-associated encephalopathy, that is
cerebral arterioles reacted to the vasodilator stimulus
slower and to a lesser extent. Besides a slower vasodila-
tion after acetazolamide administration, the maximal
dilation of the cerebral arterioles (CRC) was also lower in
septic patients. These results are in accordance with
those of Terborg and colleagues, who also demonstrated
dysfunction in patients with severe sepsis and septic
shock [7]. Similarly, animal studies have showed
decreased carbon dioxide-induced VMR in streptococcal
sepsis [20]. In recent animal models it has been shown
that microcirculatory dysfunction in the brain precedes
changes in evoked potentials [21]. Taking the absolute
blood flow velocities and pulsatility indices in the present
study into account, it is conceivable that vasoconstriction
of the cerebral arterioles may be responsible for the
impaired VMR. As shown in Table 2, pulsatility indices
were higher throughout the entire course of the acetazol-
amide test among septic patients compared with control
persons, suggesting vasoconstriction of the resistance
vessels. Although there was a slight difference between
diastolic pressures of septic and control persons, it has to
be noted that mean arterial pressures in the two groups
were similar and therefore the significance of this BP dif-
ference during transcranial doppler sonography (TCD) -
acetazolamide testing most probably did not influence
the results.
Conclusions
The clinical signficance of the present study may be sum-
marized as follows. First, the results of the transcranial
Doppler acetazolamide test may help to better under-
stand the pathophysiology of septic encephalopathies.
Second, as we mentioned above, cerebral autoregulation
and metabolic regulation occur at the same level of the
cerebral circulation (resistance arterioles). In our series of
septic patients without hemodynamic compromise or
need of hemodynamic support, the ability of the brain
resistance arterioles to dilate was decreased. If it is con-
sidered that sepsis-associated shock situations and sud-
den decreases of cerebral perfusion pressure evoke a
strong autoregulatory response, an already reduced vaso-
dilatory capacity should limit both the static and dynamic
autoregulatory response of the cerebral arterioles. One of
the most important functions of cerebral autoregulation
Figure 1 Percentage increase of the middle cerebral artery mean 
blood flow velocity in patients with sepsis-associated encephal-
opathy and in controls at 5, 10, 15 and 20 minutes after injection 
of acetazolamide. Means and standard errors are shown.
Figure 2 Maximal percentage increase of the middle cerebral ar-
tery mean blood flow velocity in patients with sepsis-associated 
encephalopathy and in controls after injection of acetazolamide. 
Means and standard errors are shown.
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oxygen delivery) during changes in systemic blood pres-
sure. Further studies are needed to clarify the importance
of hemodynamic monitoring and proper hemodynamic
support in early phases of sepsis (and sepsis-related
encephalopathy is an early warning sign), in order to pre-
vent critical blood pressure changes in the cerebral vascu-
lar bed and thus the progression of brain damage.
Key messages
• Cerebral arteriolar function is altered in sepsis-asso-
ciated encephalopathy
• Cerebral arterioles of patients with SAE react lesser
extent to vasodilatory stimuli
• Cerebral hemodynamic changes may be involved in
the early pathogenetic phases of SAE
Table 2: Systolic, diastolic and mean blood flow velocities (cm/s) and pulsatility indices before and after administration of 
acetazolamide in control persons and in patients with sepsis-associated encephalopathy
Time after acetazolamide 
(minutes)
Sepsis
(n = 14)
Control
(n = 20)
P value
Systolic blood flow velocity
0 85.4 ± 20.7 85.9 ± 13.7 0.94
5 99.6 ± 31.6 114.1 ± 20.5 0.15
10 96.5 ± 24.2 118.5 ± 19.5 < 0.05
15 101.9 ± 27.1 124.4 ± 17.5 < 0.05
20 102.0 ± 27.7 121.9 ± 17.4 < 0.05
Diastolic blood flow velocity
0 32.5 ± 12.3 45.6 ± 8.8 < 0.01
5 35.9 ± 12.5 61.9 ± 12.6 < 0.001
10 40.1 ± 13.3 64.2 ± 13.9 < 0.001
15 43.2 ± 17.4 64.4 ± 11.7 < 0.001
20 40.0 ± 12.6 80.4 ± 14.3 < 0.001
Mean blood flow velocity
0 47.9 ± 14.5 58.2 ± 12.0 < 0.05
5 55.4 ± 18.2 77.8 ± 17.1 < 0.01
10 56.4 ± 16.0 79.3 ± 16.6 < 0.001
15 59.4 ± 19.4 64.4 ± 11.7 < 0.01
20 58.7 ± 17.5 80.4 ± 14.3 < 0.001
Pulsatility index
0 1.15 ± 0.35 0.85 ± 0.20 < 0.01
5 1.21 ± 0.26 0.80 ± 0.16 < 0.001
10 1.01 ± 0.32 0.70 ± 0.16 < 0.01
15 0.98 ± 0.34 0.76 ± 0.15 < 0.05
20 1.06 ± 0.24 0.74 ± 0.14 < 0.01
Means and standard deviations are shown.
Figure 3 Illustration of the rationale and the background of tran-
scranial Doppler-assessed cerebral vasomotor reactivity testing. 
MCA: middle cerebral artery.
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